Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

31.83

+0.01 (0.03%)

as of Jul 15, 2026, 3:23:30 pm Market Open.

69 watching

Investor Insights

Jul 15, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical (TEVA-N) is experiencing a significant turnaround under its current CEO, with a remarkable 264% increase since January 2023. The demand for GLP (glucagon-like peptides) remains strong; however, the entry of more generics into the market could lead to declining prices. While analysts highlight the potential for innovation, concerns remain about Teva's lack of innovative capabilities. The stock has shown strong momentum, breaking out over $21 in September and maintaining positive accumulation trends for the past six months. Despite not offering dividends, analysts have set a price target of $34.50 for the stock, indicating further potential growth amidst favorable market conditions for drug stocks.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer,PFE

BUY

Trading down 5% on a one-year basis and 14 X forward earnings. This would be a more conservative buy then Gilead (GILD-Q).

TOP PICK

World's leading generic drug manufacturer. Buying Barr Laboratories, which will broaden its product range and increase its strength. Generic drugs are a solution to a lot of the problems that are facing the global health industry.

TOP PICK

Largest generic drug company in the world. Company outlook was better than what the Street was looking for. People are moving more towards generics as economies weaken. (Recommends you do partial buys on a gradual basis.)

PAST TOP PICK

(Top Pick Oct 23/07, Down 4%). World’s largest generic drug manufacturer; owns some brand name drugs, picks up drugs when they go off patent. Combine with owning a brand name drug company in portfolio. It’s a buy today. 3-5 years down the road, growth is in drugs coming off patent.

TOP PICK

Biggest Generic Drug manufacturer, getting into Japan where only a small percentage is generic. Strong cash flow.

PAST TOP PICK

(A Top Pick Sept 11/07. Up 12%.) Generics are the best place to be in pharmaceuticals. This is the largest, the leader and the fastest growing. Has the best products coming on. Have made some great acquisitions.

COMMENT

An interesting stock as this is one of the best generic drug manufacturers. Increasingly, as the blockbuster drugs do come off patent, there is probably more upside with the generics. Not a fan of pharmaceuticals because of the potential for litigation.

COMMENT

Global pharmaceutical. In a trading range for almost a year. Not a particularly high R & D industry. A lot of generics. It might add a lot of stability to a portfolio. Prefers Johnson & Johnson (JNJ-N).

TOP PICK

Leading by far the number of potential drugs that they can manufacture. Very well tied in to the Israeli technology sector. Have the first drug that shows a reduced effect of Parkinson's.

TOP PICK

Largest generic drug manufacturer globally. Acquiring Barr Labs (BRL-N) giving them more international exposure. Also have some proprietary drugs, most importantly a Parkinson drug.

TOP PICK

Largest generic drug company in the world. Have the leading drug for multiple sclerosis that is going to be produced generically by competition but will take 3 or 4 years. Just announced 3rd stage of a drug for Parkinson’s that is the only one that has slowed and possibly stopped the progression of Parkinson's. Has many years of patent protection.

BUY

(Market Call Minute.) Biggest generic drug manufacturer in the world. More and more drugs are coming off patent so the growth outlook is fabulous.

DON'T BUY

Beneficiaries of the branded drug companies’ losses are generic manufacturers. This one is the largest. Not sure if the timing is exactly appropriate right now, but on a longer-term perspective, this should benefit with generic drug manufacturing.

TOP PICK

This pharmaceutical is in the sweet spot. The world's largest generic drug company. Also have proprietary drugs that it has developed on its own. They have been the main beneficiary of the switch from big name patented drugs to off-patent drugs. Have about 18% of the US generics and are working towards 30% through acquisitions and generics as drugs go off patent. 1% dividend only, because it is a growth company. The stock has a long way to go.

BUY

Largest generic drug manufacturer globally. Had a bit of a correction when the head of its North American operations resigned and was replaced. He has a 2-pronged approach to the drug industry. This is his growth generic company and he owns Pfizer (PFE-N) as his value dividend play.

Showing 211 to 225 of 276 entries

Most Recent Experts

Colin Cieszynski

SIA Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)